IS8234A - Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði - Google Patents
Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræðiInfo
- Publication number
- IS8234A IS8234A IS8234A IS8234A IS8234A IS 8234 A IS8234 A IS 8234A IS 8234 A IS8234 A IS 8234A IS 8234 A IS8234 A IS 8234A IS 8234 A IS8234 A IS 8234A
- Authority
- IS
- Iceland
- Prior art keywords
- methylsulfonyl
- thio
- hydroxyphenyl
- phenoxy
- oxy
- Prior art date
Links
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 title 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 title 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 235000019260 propionic acid Nutrition 0.000 title 1
- 159000000000 sodium salts Chemical class 0.000 title 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/06—Potassium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/04—Sodium compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314131.4A GB0314131D0 (en) | 2003-06-18 | 2003-06-18 | Therapeutic agents |
| PCT/GB2004/002595 WO2004113284A1 (en) | 2003-06-18 | 2004-06-16 | Potassium or sodium salt of (-)-2-{`2-(4-hydroxyphenyl)ethyl!-thio-3-`4-(2-{4-`(methzlsulfonzl) oxy !phenoxy}phenyl!propanoic acid and their use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8234A true IS8234A (is) | 2006-01-16 |
Family
ID=27636790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8234A IS8234A (is) | 2003-06-18 | 2006-01-16 | Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070099997A1 (is) |
| EP (1) | EP1641749A1 (is) |
| JP (1) | JP2006527750A (is) |
| KR (1) | KR20060026427A (is) |
| CN (1) | CN1835920A (is) |
| AR (1) | AR044800A1 (is) |
| AU (1) | AU2004249485A1 (is) |
| BR (1) | BRPI0411515A (is) |
| CA (1) | CA2529251A1 (is) |
| CO (1) | CO5650240A2 (is) |
| GB (1) | GB0314131D0 (is) |
| IL (1) | IL172440A0 (is) |
| IS (1) | IS8234A (is) |
| MX (1) | MXPA05013826A (is) |
| NO (1) | NO20055927L (is) |
| RU (1) | RU2005141068A (is) |
| TW (1) | TW200503679A (is) |
| UY (1) | UY28367A1 (is) |
| WO (1) | WO2004113284A1 (is) |
| ZA (1) | ZA200510196B (is) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104333D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| ES2299702T3 (es) | 2002-06-20 | 2008-06-01 | Astrazeneca Ab | Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina. |
| GB0314075D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0427524D0 (en) | 2004-12-16 | 2005-01-19 | Astrazeneca Ab | Chemical process |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5232945A (en) * | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| SE0000772D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| TWI311133B (en) * | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| NZ531796A (en) * | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
| SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
-
2003
- 2003-06-18 GB GBGB0314131.4A patent/GB0314131D0/en not_active Ceased
-
2004
- 2004-06-16 AU AU2004249485A patent/AU2004249485A1/en not_active Abandoned
- 2004-06-16 MX MXPA05013826A patent/MXPA05013826A/es unknown
- 2004-06-16 WO PCT/GB2004/002595 patent/WO2004113284A1/en active Application Filing
- 2004-06-16 EP EP04742954A patent/EP1641749A1/en not_active Withdrawn
- 2004-06-16 US US10/561,170 patent/US20070099997A1/en not_active Abandoned
- 2004-06-16 RU RU2005141068/04A patent/RU2005141068A/ru not_active Application Discontinuation
- 2004-06-16 KR KR1020057024249A patent/KR20060026427A/ko not_active Application Discontinuation
- 2004-06-16 CA CA002529251A patent/CA2529251A1/en not_active Abandoned
- 2004-06-16 BR BRPI0411515-5A patent/BRPI0411515A/pt not_active IP Right Cessation
- 2004-06-16 CN CNA2004800232944A patent/CN1835920A/zh active Pending
- 2004-06-16 JP JP2006516434A patent/JP2006527750A/ja active Pending
- 2004-06-17 AR ARP040102110A patent/AR044800A1/es not_active Application Discontinuation
- 2004-06-17 UY UY28367A patent/UY28367A1/es not_active Application Discontinuation
- 2004-06-18 TW TW093117729A patent/TW200503679A/zh unknown
-
2005
- 2005-12-07 IL IL172440A patent/IL172440A0/en unknown
- 2005-12-13 NO NO20055927A patent/NO20055927L/no not_active Application Discontinuation
- 2005-12-14 ZA ZA200510196A patent/ZA200510196B/en unknown
- 2005-12-29 CO CO05131305A patent/CO5650240A2/es not_active Application Discontinuation
-
2006
- 2006-01-16 IS IS8234A patent/IS8234A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20055927L (no) | 2006-01-27 |
| WO2004113284A1 (en) | 2004-12-29 |
| CA2529251A1 (en) | 2004-12-29 |
| GB0314131D0 (en) | 2003-07-23 |
| US20070099997A1 (en) | 2007-05-03 |
| TW200503679A (en) | 2005-02-01 |
| MXPA05013826A (es) | 2006-02-28 |
| IL172440A0 (en) | 2006-04-10 |
| CO5650240A2 (es) | 2006-06-30 |
| ZA200510196B (en) | 2006-12-27 |
| KR20060026427A (ko) | 2006-03-23 |
| EP1641749A1 (en) | 2006-04-05 |
| AR044800A1 (es) | 2005-10-05 |
| AU2004249485A1 (en) | 2004-12-29 |
| UY28367A1 (es) | 2005-01-31 |
| JP2006527750A (ja) | 2006-12-07 |
| RU2005141068A (ru) | 2007-07-27 |
| BRPI0411515A (pt) | 2006-08-01 |
| CN1835920A (zh) | 2006-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8224A (is) | Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði | |
| LU92025I2 (fr) | Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique | |
| IL186435A (en) | Pharmaceutical formulation for oral administration of choline salt of acid 2 - [4 - (4 - chlorobenzoyl) phenoxy] - 2 - methyl propanoic | |
| EE200200284A (et) | (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe peenestatud vorm | |
| CY1109299T1 (el) | Μεθανοσουλφονικο αλας 3-[(2-{[4-εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλο-αμινο]-προπιονικου αιθυλεστερα και η χρηση αυτου ως φαρμακευτικο μεσο | |
| IS8234A (is) | Kalíum- eða natríumsalt (-)-2-{[2-(4-hýdroxýfenýl)etýl]þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}fenýl]própansýru og notkun þeirra í læknisfræði | |
| EP1937065A4 (en) | LYSINE SALTS OF 4 - ((PHENOXYALKYL) THIO) -PHENOXYACETIC ACID DERIVATIVES | |
| DE602004022179D1 (de) | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga | |
| FR2877112B3 (fr) | Procede de gestion de fenetres d'affichage | |
| PT1471057E (pt) | Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2 | |
| FR2873385B1 (fr) | Surveillance et controle d'une electroporation | |
| DE60127466D1 (de) | Gewinnung von natriumchlorid und anderen salzen aus sole | |
| IL172376A0 (en) | Process for the preparation of racemic 2{[2-(4- hydroxyphenyl)ethyl]thio}-3-[4-(2-{4- [(methylsulphonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid | |
| DE602004028500D1 (de) | 4-((phenoxyalkyl)thio)-phenoxyessigsäuren und analoga | |
| DE602004018622D1 (de) | Pharmazeutische zusammensetzung enthaltend 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylessigsäure | |
| CO5590908A2 (es) | Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa | |
| TW200640843A (en) | Therapeutic agents | |
| DE60316792D1 (de) | Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen | |
| IS7056A (is) | Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín | |
| ATE423569T1 (de) | Verwendung von hitzelabilem escherichia-coli- toxin als adjuvans bei geflügel | |
| FR2879312B1 (fr) | Procede d'ecriture et de restauration de donnees de conservation | |
| DE60328787D1 (de) | Pharmazeutische salze von reboxetin | |
| IS7057A (is) | Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og súlónýlþvagefni | |
| IS7058A (is) | Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf | |
| ITMI20040802A1 (it) | Polimorfi di pantoprazolo sale sodico e procedimento per la loro preparazione |